Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).
Last trade$0.7502
Day change-$0.0568 (-7.04%)
Day range$0.746 – $0.818
Volume5,347,770
Market cap$280M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$280.64M
Price / earnings
—
Price / book
0.71×
Price / sales
60.48×
EV / sales
54.17×
EV / EBITDA
-1.4×
Profitability
Earnings per share
-$0.50
Return on assets
-34.12%
Return on equity
-44.44%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
7.79×
Quick ratio
7.79×
Cash ratio
0.76×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$108.81M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for ALLO, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$4.64M
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$4.64M
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$12.86M
$20.84M
$14.09M
$13.77M
$13.74M
$14.28M
$14.99M
$15.52M
Research and development
$41.93M
$30.72M
$32M
$28.63M
$31.16M
$40.16M
$50.2M
$44.97M
Total operating expenses
$54.79M
$51.56M
$46.09M
$42.4M
$44.9M
$56.82M
$65.19M
$60.49M
Operating income
-$54.79M
-$46.92M
-$46.09M
-$42.4M
-$44.9M
-$56.82M
-$65.19M
-$60.49M
Interest expense
-$379K
-$343K
-$300K
-$313K
-$344K
-$268K
-$150K
-$81K
Income before taxes
-$50.37M
-$42.68M
-$42.61M
-$38.81M
-$41.4M
-$50.94M
-$59.73M
-$59.5M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$443K
Net income
-$50.37M
-$42.68M
-$42.61M
-$38.81M
-$41.4M
-$50.94M
-$59.73M
-$59.94M
Net income attributable to common shareholders
-$50.37M
-$42.68M
-$42.61M
-$38.81M
-$41.4M
-$50.94M
-$59.73M
-$59.94M
EBITDA
-$52.21M
-$44.28M
-$43.22M
-$39.35M
-$41.8M
-$51.33M
-$62.09M
-$57.26M
Basic earnings per share
-$0.15
-$0.13
-$0.18
-$0.17
-$0.19
-$0.23
-$0.28
-$0.28
Diluted earnings per share
-$0.15
-$0.13
-$0.18
-$0.17
-$0.19
-$0.23
-$0.28
-$0.28
Recent news
Company coverage with links to the original publishers.
Allogene Therapeutics announced preliminary Phase 1 data from the RESOLUTION study of ALLO-329, an allogeneic CAR T therapy for autoimmune diseases. The trial showed a favorable safety profile with no dose-limiting toxicities, ICANS, GvHD, or Grade ≥3 CRS events in 18 patients. In 10 patients with systemic sclerosis, 8 achieved clinically meaningful improvements in skin scores across all lymphodepletion approaches, including without lymphodepletion, with 9 remaining off immunosuppressive therapy.
Allogene Therapeutics priced an underwritten public offering of 87.5 million shares at $2.00 per share, raising $175 million in gross proceeds. The company plans to use net proceeds for clinical trials, R&D, and general corporate purposes. The offering is expected to close on April 16, 2026, with Goldman Sachs, Jefferies, and TD Cowen serving as joint bookrunners.
Allogene Therapeutics won an arbitration against Cellectis regarding CAR-T therapy development rights, securing full control of cemacabtagene ansegedleucel in the U.S., EU, and U.K., while the tribunal rejected Cellectis's financial claims and allegations.
Allogene Therapeutics won a favorable arbitration ruling with Cellectis, reconfirming full development and commercial control of cemacabtagene ansegedleucel (cema-cel) in the US, EU, and UK, with a path to acquire full global rights by 2026.
The U.S. CAR T-cell therapies market is expected to grow from USD 3.43 billion in 2026 to USD 42.61 billion by 2035, driven by rising cancer cases, research investments, and innovative therapeutic approaches.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.